Novavax, Inc. (NVAX)

6.53 +0.37 (+5.93%) As of 02:05PM EDT. Market open.

Novavax, Inc.

21 Firstfield Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,992

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James Patrick Kelly C.F.A.	Exec. VP, CFO & Treasurer	355.23k	N/A	1966
Mr. John A. Herrmann III	Exec. VP, Chief Legal Officer & Corp. Sec.	657.8k	14.2M	1966
Mr. Stanley Charles Erck	Advisor	1.12M	28.63M	1948
Mr. John Joseph Trizzino B.S., M.B.A.	Exec. VP and Chief Bus. & Commercial Officer	636.85k	13.33M	1960
Dr. Gregory M. Glenn M.D.	Pres of R&D	813.44k	29.02M	1954
Mr. John Charles Jacobs M.B.A.	Pres, CEO & Director	N/A	N/A	1968
Mr. Richard P. Crowley	Exec. VP & COO	N/A	N/A	1957
Dr. Gale E. Smith	Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist	N/A	N/A	1950
Mr. Biegie Lee	Sr. VP & Chief Information Officer	N/A	N/A	N/A
Mr. Troy Morgan Esq., J.D.	Sr. VP & Chief Compliance Officer	N/A	N/A	1971

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate governance

Novavax, Inc.’s ISS governance QualityScore as of 1 March 2023 is 5. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.